lansoprazole Side Effects
Also known as: Prevacid
Analysis of 173,086 adverse event reports submitted to the FDA from 1997 to 2025.
Total Reports
173,086
Death-Related
19,347
11.2% of reports
Hospitalizations
62,821
36.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 19,347 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 4,505 |
| CHRONIC KIDNEY DISEASE | 3,581 |
| RENAL FAILURE | 2,756 |
| ACUTE KIDNEY INJURY | 2,704 |
| END STAGE RENAL DISEASE | 2,231 |
| PNEUMONIA | 1,611 |
| VOMITING | 1,580 |
| DYSPNOEA | 1,496 |
| DIARRHOEA | 1,470 |
| NAUSEA | 1,352 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,325 |
| OFF LABEL USE | 1,296 |
| CONDITION AGGRAVATED | 1,258 |
| PYREXIA | 1,172 |
| HYPERTENSION | 1,170 |
| FATIGUE | 1,129 |
| ASTHENIA | 1,095 |
| LOWER RESPIRATORY TRACT INFECTION | 1,053 |
| DECREASED APPETITE | 1,052 |
| PAIN | 1,046 |
Reactions in Hospitalization Reports
Top reactions in 62,821 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DIARRHOEA | 4,794 |
| DYSPNOEA | 4,385 |
| VOMITING | 4,321 |
| ACUTE KIDNEY INJURY | 4,195 |
| NAUSEA | 4,039 |
| PYREXIA | 3,747 |
| PNEUMONIA | 3,556 |
| FATIGUE | 3,274 |
| MALAISE | 3,079 |
| OFF LABEL USE | 2,949 |
| ASTHENIA | 2,896 |
| PAIN | 2,847 |
| RENAL FAILURE | 2,766 |
| ABDOMINAL PAIN | 2,748 |
| HEADACHE | 2,697 |
| CHEST PAIN | 2,659 |
| CONFUSIONAL STATE | 2,616 |
| DIZZINESS | 2,573 |
| FALL | 2,569 |
| CHRONIC KIDNEY DISEASE | 2,494 |
Nearby — Related Medications
What the FAERS Data Reveals About lansoprazole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 173,086 voluntary reports linked to lansoprazole and its brand equivalents (Prevacid), spanning 1997 through 2025. Of those, 19,347 (11.2%) listed death as an outcome and 62,821 (36.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 45-64, with 36,053 reports in that bracket. The single most reported reaction is chronic kidney disease with 32,775 submissions, followed by acute kidney injury and renal failure.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.